Compare AESI & RAPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AESI | RAPT |
|---|---|---|
| Founded | 2017 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.7B |
| IPO Year | 2023 | 2019 |
| Metric | AESI | RAPT |
|---|---|---|
| Price | $9.94 | $58.00 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 6 | 10 |
| Target Price | $11.40 | ★ $56.22 |
| AVG Volume (30 Days) | 2.0M | ★ 4.6M |
| Earning Date | 05-25-2026 | 01-01-0001 |
| Dividend Yield | ★ 5.04% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,095,310,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $13.67 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 3.73 | N/A |
| 52 Week Low | $7.64 | $0.71 |
| 52 Week High | $19.00 | $58.02 |
| Indicator | AESI | RAPT |
|---|---|---|
| Relative Strength Index (RSI) | 39.01 | 78.57 |
| Support Level | $8.90 | $32.00 |
| Resistance Level | $12.33 | N/A |
| Average True Range (ATR) | 0.74 | 0.09 |
| MACD | -0.22 | -0.79 |
| Stochastic Oscillator | 21.55 | 90.91 |
Atlas Energy Solutions Inc is a provider of proppant and logistics services to the oil and natural gas industry within the Permian Basin of West Texas and New Mexico, the most active oil and natural gas basin in North America. Proppant is necessary to facilitate the recovery of hydrocarbons from oil and natural gas wells. One hundred percent of its sand reserves are located in Winkler and Ward Counties, Texas, within the Permian Basin, and its operations consist of proppant production and processing facilities, including two facilities near Kermit, Texas, and a third facility near Monahans, Texas.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.